We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AbbVie Opens First Phase of Singapore Facility
News

AbbVie Opens First Phase of Singapore Facility

AbbVie Opens First Phase of Singapore Facility
News

AbbVie Opens First Phase of Singapore Facility

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AbbVie Opens First Phase of Singapore Facility"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AbbVie has strengthened its manufacturing capabilities by opening the small molecule active pharmaceutical ingredient (API) facility of its Singapore manufacturing site. This facility supports the growth of AbbVie's oncology and women's health pipeline and reflects progress from AbbVie's two previous announcements for manufacturing investment in Asia in 2014.

The new 120,000 square-meter site – located in the Tuas Biomedical Park – is AbbVie's first manufacturing facility in Asia and will also include a biologics manufacturing facility that is expected to be fully operational by the end of 2018. Combined, the API and biologics facilities represent a $320 million (more than S$400 million) investment in Singapore that will employ more than 250 new employees, the majority of whom will be hired locally in Singapore, including skilled positions across manufacturing, technical operations, administration, quality, information technology and supply chain.

"Our goal as AbbVie is to assure patients around the world have access to new and innovative medicines when they need them and where they need them," said Azita Saleki-Gerhardt, Ph.D., senior vice president, operations, AbbVie. "Today, with the opening of the first phase of our Singapore facility, we will further strengthen our manufacturing capabilities and continue to enhance our support of AbbVie's pipeline in the therapeutic areas of oncology and women's health for patients around the world."

Speaking at the opening ceremony, Site Director Marc O'Donoghue, Ph.D., added, "Singapore is recognized as a leader in the biopharmaceutical industry and AbbVie is excited to open its facility and begin operations. Singapore has a robust infrastructure, a highly educated and skilled workforce and provides a supportive environment for manufacturing. Our presence in Singapore establishes AbbVie's footprint in Asia and provides geographic balance in AbbVie's manufacturing network to ensure continuity of supply."

"AbbVie's choice of Singapore for its first in Asia manufacturing facility is testament to our capabilities as a high-quality, global biopharmaceutical manufacturing hub. Given our track record of providing a world-class business environment and skilled talent pool to companies, we enable companies such as AbbVie to develop and manufacture innovative products to deliver value for patients worldwide," said Ms. Weng Si Ho, director, biomedical sciences, Singapore Economic Development Board (EDB).

"EDB will continue to commit strong investments in talent, infrastructure and technology to support the strong growth in the biopharmaceutical industry." AbbVie's manufacturing network now includes 13 locations across the United States, Europe, Asia and Puerto Rico, as well as strategic partnerships with third-party manufacturers.

Advertisement